Hypertrophic scars and keloids: a review and current treatment modalities
Abstract Hypertrophic scars (HTS) are raised, red, rigid, inflexible cell-like, and cosmetic problems precipitated due to multiple underlying dermal injuries such as burn, surgery, and trauma during which aberrant wound healing with more pathological deposition of the extracellular matrix than degradation leads to their spawning. Till date, well established and specific treatments for HTS have not been reported; hence, the need of recent developments is thrusted with novel drug delivery vision. This review will try to encompass all the agogs to HTS, definition, pathophysiology, mechanism of hypertrophic scar formation, the role of growth factors in hypertrophic scarring, and their difference with keloids. Further, it will illuminate the available medicaments and recent advances in novel topical drug delivery systems such as ethosomes, transethosomes, liposomes, solid lipid nanoparticles, and microsponges for treatment of HTS..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Biomedical dermatology - 4(2020), 1 vom: 20. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tripathi, Sanjeev [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Endocrinological hypothesis |
| doi: |
10.1186/s41702-020-00063-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR039764109 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR039764109 | ||
| 003 | DE-627 | ||
| 005 | 20230519183903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s41702-020-00063-8 |2 doi | |
| 035 | |a (DE-627)SPR039764109 | ||
| 035 | |a (SPR)s41702-020-00063-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 082 | 0 | 4 | |a 610 |a 530 |a 570 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Tripathi, Sanjeev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertrophic scars and keloids: a review and current treatment modalities |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Hypertrophic scars (HTS) are raised, red, rigid, inflexible cell-like, and cosmetic problems precipitated due to multiple underlying dermal injuries such as burn, surgery, and trauma during which aberrant wound healing with more pathological deposition of the extracellular matrix than degradation leads to their spawning. Till date, well established and specific treatments for HTS have not been reported; hence, the need of recent developments is thrusted with novel drug delivery vision. This review will try to encompass all the agogs to HTS, definition, pathophysiology, mechanism of hypertrophic scar formation, the role of growth factors in hypertrophic scarring, and their difference with keloids. Further, it will illuminate the available medicaments and recent advances in novel topical drug delivery systems such as ethosomes, transethosomes, liposomes, solid lipid nanoparticles, and microsponges for treatment of HTS. | ||
| 650 | 4 | |a Hypertrophic scar |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Wound healing |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Endocrinological hypothesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Role of growth factors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Role of HMGB-1in HTS |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Topical Novel DDS |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Soni, Kumud |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Poornima |e verfasserin |4 aut | |
| 700 | 1 | |a Gour, Vishal |e verfasserin |4 aut | |
| 700 | 1 | |a Mondal, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Soni, Vandana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedical dermatology |d London : BioMed Central, 2017 |g 4(2020), 1 vom: 20. Mai |w (DE-627)SPR038289814 |w (DE-600)2886509-1 |x 2398-8460 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2020 |g number:1 |g day:20 |g month:05 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s41702-020-00063-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 4 |j 2020 |e 1 |b 20 |c 05 | ||